Cargando…

Novel glutamatergic drugs for the treatment of mood disorders

Mood disorders are common and debilitating, resulting in a significant public health burden. Current treatments are only partly effective and patients who have failed to respond to trials of existing antidepressant agents (eg, those who suffer from treatment-resistant depression [TRD]) require innov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lapidus, Kyle AB, Soleimani, Laili, Murrough, James W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/ https://www.ncbi.nlm.nih.gov/pubmed/23976856 http://dx.doi.org/10.2147/NDT.S36689

Ejemplares similares

Disturbance of the Glutamatergic System in Mood Disorders
por: Jun, Chansoo, et al.
Publicado: (2014)

Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status“
por: Pappagallo, Marco, et al.
Publicado: (2022)

Improving Mood Promoting Access to Collaborative Treatment (IMPACT) Program in Geriatrics Primary Care
por: Baharlou, Shahla, et al.
Publicado: (2021)

Application of Antipsychotic Drugs in Mood Disorders
por: Rybakowski, Janusz K.
Publicado: (2023)

Targeting the Glutamatergic System for the Treatment of HIV-Associated Neurocognitive Disorders
por: Potter, Michelle C., et al.
Publicado: (2013)

The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders
por: Munshi, Kaizad R., et al.
Publicado: (2010)

Autism Spectrum Disorder: Focus on Glutamatergic Neurotransmission
por: Montanari, Martina, et al.
Publicado: (2022)

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
por: Kadriu, Bashkim, et al.
Publicado: (2018)

Glutamatergic augmentation strategies in obsessive–compulsive disorder
por: Sheshachala, Karthik, et al.
Publicado: (2019)

Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders
por: Grinchii, Daniil, et al.
Publicado: (2020)

Astrocytic Glutamatergic Transmission and Its Implications in Neurodegenerative Disorders
por: Satarker, Sairaj, et al.
Publicado: (2022)

Role of nucleus accumbens glutamatergic plasticity in drug addiction
por: Quintero, Gabriel C
Publicado: (2013)

Sirukumab: A Potential Treatment for Mood Disorders?
por: Zhou, Aileen J., et al.
Publicado: (2016)

Pharmacogenomics of Mood Stabilizers in the Treatment of Bipolar Disorder
por: Squassina, Alessio, et al.
Publicado: (2010)

Inflammation as a treatment target in mood disorders: review
por: Jones, Brett D. M., et al.
Publicado: (2020)

Treatment for illegal drug use disorders: the role of comorbid mood and anxiety disorders
por: Melchior, Maria, et al.
Publicado: (2014)

Restoring tripartite glutamatergic synapses: A potential therapy for mood and cognitive deficits in Gulf War illness
por: Wang, Xueqin, et al.
Publicado: (2020)

Self‐medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature
por: Turner, Sarah, et al.
Publicado: (2018)

Glutamatergic dysfunction in Schizophrenia
por: Kruse, Andreas O., et al.
Publicado: (2022)

Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies
por: Li, Cheng-Ta, et al.
Publicado: (2019)

Light treatment of mood disorders
por: Parry, Barbara L., et al.
Publicado: (2003)

Prazosin during threat discrimination boosts memory of the safe stimulus
por: Homan, Philipp, et al.
Publicado: (2017)

Disruptive mood dysregulation disorder: current insights
por: Baweja, Raman, et al.
Publicado: (2016)

Glutamatergic transmission in drug reward: implications for drug addiction
por: D'Souza, Manoranjan S.
Publicado: (2015)

Glix 13, a New Drug Acting on Glutamatergic Pathways in Children and Animal Models of Autism Spectrum Disorders
por: Santini, Annamaria Chiara, et al.
Publicado: (2014)

Reporting guidelines on remotely collected electronic mood data in mood disorder (eMOOD)—recommendations
por: Faurholt-Jepsen, Maria, et al.
Publicado: (2019)

Brain stimulation in posttraumatic stress disorder
por: Novakovic, Vladan, et al.
Publicado: (2011)

Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence
por: Jones, Brett D. M., et al.
Publicado: (2021)

The Genetic Side of the Mood: A Scientometric Review of the Genetic Basis of Mood Disorders
por: Bonacina, Giovanni, et al.
Publicado: (2023)

Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder
por: Ting, Jonathan T, et al.
Publicado: (2008)

Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery
por: Cieślik, Paulina, et al.
Publicado: (2020)

Pharmacological effects of berberine on mood disorders
por: Fan, Jie, et al.
Publicado: (2018)

RNA Editing and Modifications in Mood Disorders
por: Barbon, Alessandro, et al.
Publicado: (2020)

Hypothyroidism and mood disorders: integrating novel insights from brain imaging techniques
por: Pilhatsch, Maximilian, et al.
Publicado: (2011)

Editorial: Novel Approaches to Improve Detection, Differentiation and Treatment in Mood Disorders
por: Abdel Aziz, Karim, et al.
Publicado: (2022)

Glucocorticoid receptor dysfunction: consequences for the pathophysiology and treatment of mood disorders
por: Abraham, Aju, et al.
Publicado: (2003)

Borderline Personality Disorder: Bipolarity, Mood Stabilizers and Atypical Antipsychotics in Treatment
por: Belli, Hasan, et al.
Publicado: (2012)

Mood Disorders: From Psychopathogenesis to Treatment
por: Lu, Ru-Band
Publicado: (2015)

Editorial: Novel Approaches to the Neuropharmacology of Mood Disorders
por: Caruncho, Hector J., et al.
Publicado: (2019)

Overview of Glutamatergic Dysregulation in Central Pathologies
por: Miladinovic, Tanya, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_louqabbshevemhuvdhhrpilq3n